$ZLCS Zalicus Inc. Company Overview
Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. It has a portfolio of clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.
ZLCS Last Price: 1.22
Last Updated: November 28, 2013 8:15 PM EST
ZLCS Stock Message Board and Forum http://investorshangout.com/search?q=ZLCS&...mp;yt0=Go!
Zalicus Inc. ZLCS Officers and Executives
Name Age Officer Since Title
Mr. Frank W. Haydu 65 2004 Chairman
Dr. Mark H. N. Corrigan 55 2009 President, Chief Executive Officer & Director
Mr. Justin A. Renz 41 2006 Chief Financial Officer, Treasurer & Executive VP
Mr. William James O'Shea 63 2007 Independent Director
Dr. William L. Hunter 50 2009 Independent Director
Zalicus, Inc.
245 1st Street
3rd floor
Cambridge, Massachusetts 02142
Phone
1 6173017000
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$12.55M
Net Income
$-44.33M
2012 Sales Growth
53.3%
Employees
36.00
Annual Report Below for ZLCS
Zalicus Inc. ZLCS Recent Headlines
MarketWatch News on ZLCS
Zalicus to discontinue rheumatoid arthritis drug 10:38 a.m. Sept. 10, 2012 - MarketWatch.com
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday’s biggest advancing and declining stocks 2:35 p.m. July 5, 2011 - Kate Gibson
Drug stocks sluggish; Zalicus jumps 12:17 p.m. July 5, 2011 - Val Brickates Kennedy
Zalicus jumps 10% on stock rating 9:18 a.m. July 5, 2011 - Val Brickates Kennedy
5 reasons I can’t sell B. of A. — should you buy? 8:42 a.m. April 21, 2011 - Jeff Reeves
10 expert stock picks for 2011 12:02 a.m. Jan. 5, 2011 - Jeff Reeves
Zalicus trades sharply higher on heavy volume 1:28 p.m. Nov. 26, 2013 - Seeking Alpha
Zalicus: Where From Here? 12:02 p.m. Nov. 15, 2013 - Seeking Alpha
UPDATE: Oppenheimer Downgraded Zalicus 2:48 p.m. Nov. 11, 2013 - benzinga.com
Intel Buys ‘Kno’ to Reinforce Education Laptops Sideline and 2 Other Hot Stocks to Watch 11:35 a.m. Nov. 11, 2013 - Wall St. Cheat Sheet
Zalicus Plunges on Pain Drug Blowup 11:30 a.m. Nov. 11, 2013 - TheStreet.com
Zalicus' Z160 Fails, What Now? 11:05 a.m. Nov. 11, 2013 - Seeking Alpha
Zalicus: Investors Get Sucker Punched 10:58 a.m. Nov. 11, 2013 - Seeking Alpha
UPDATE: Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 7:32 a.m. Nov. 11, 2013 - benzinga.com
Key Issues Surrounding The Zalicus Catalyst Trade 8:56 a.m. Nov. 8, 2013 - Seeking Alpha
Clues And Controversy: Why Zalicus Shares Could Be Set For A Rally 9:08 a.m. Nov. 6, 2013 - Seeking Alpha
Where Is Zalicus After Trial Results? 2:06 p.m. Nov. 5, 2013 - Seeking Alpha
Recent FDA News Makes A Zalicus Trade Look Even More Compelling 5:27 a.m. Oct. 29, 2013 - Seeking Alpha
Zalicus: An Upcoming Catalyst With Huge Potential 11:06 a.m. Oct. 24, 2013 - Seeking Alpha
4 Biotechnology Stocks With Room To Climb 9:10 a.m. Oct. 15, 2013 - Seeking Alpha
A High Risk-High Reward Biopharma With Two Pending Catalysts 8:16 a.m. Oct. 4, 2013 - Seeking Alpha
Biotech Stock Mailbag: Bubble Debate, Cel-Sci, Zogenix, Zalicus 6:00 a.m. Oct. 4, 2013 - TheStreet.com
Zalicus Shares Nosedive Following News of 1-for-6 Reverse Split 3:57 p.m. Oct. 2, 2013 - benzinga.com
Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude 12:03 p.m. Oct. 2, 2013 - TheStreet.com
Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals 10:25 a.m. Sept. 20, 2013 - Seeking Alpha
AcelRx Pharmaceuticals To Submit NDA By End Of September, May Be Acquired Soon 7:55 a.m. Sept. 20, 2013 - Seeking Alpha
Press Releases on ZLCS
ELTK, AAPL, ZLCS and AGNC added to NASDAQ Active Stock Watch List at EPR 10:05 a.m. Nov. 27, 2013 - ACCESSWIRE
Bullish Stocks Analysis: Zalicus Inc, Camtek Ltd, JPMorgan Chase & Co, Nevada Gold Corp 9:01 a.m. Nov. 27, 2013 - ACCESSWIRE
Bearish Stocks Trend Analysis: Green Mountain Coffee Roasters, Zalicus Inc, Time Warner Cable, Baidu, Qihoo 360 Technology 8:47 a.m. Nov. 27, 2013 - PR Newswire
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent 8:00 a.m. Nov. 14, 2013 - PR Newswire
TrendingWallStreet.com Initiates Trend Research on TRMR, ENIP, STPFQ, and ZLCS 12:23 a.m. Nov. 13, 2013 - ACCESSWIRE
FDA Updates, Corporate Developments: Viropharma, 3D Systems Corporation, Cirrus Logic, Zalicus, The Boeing Company 8:53 a.m. Nov. 12, 2013 - PR Newswire
TrendingWallStreet.com Initiates Volume Research on TRMR, ENIP, STPFQ, and ZLCS 1:05 a.m. Nov. 12, 2013 - ACCESSWIRE
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR 10:19 a.m. Nov. 11, 2013 - ACCESSWIRE
Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 8:30 a.m. Nov. 11, 2013 - BusinessWire
Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena, Zalicus, Infinity, Stemline and Insmed 8:00 a.m. Nov. 5, 2013 - PR Newswire
Zalicus Reports Financial Results for the Third Quarter 2013 7:30 a.m. Nov. 4, 2013 - BusinessWire
Zalicus Announces Positive Results of Z944 Phase 1b Clinical Study in Pain 8:30 a.m. Nov. 1, 2013 - BusinessWire
Under The Radar Big Pharma Partnership Opportunity for Zalicus,Targacept and ACADIA 5:16 a.m. Oct. 31, 2013 - ACCESSWIRE
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 9:00 a.m. Oct. 30, 2013 - PR Newswire
Zalicus Regains Compliance with Nasdaq Listing Requirements 7:30 a.m. Oct. 15, 2013 - BusinessWire
Zalicus Announces 1-for-6 Reverse Stock Split 4:01 p.m. Oct. 2, 2013 - BusinessWire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 8:00 a.m. Oct. 2, 2013 - PR Newswire
TSLA, AGNC, GERN and ZLCS added to Nasdaq Active Stock Watch List at GSR 9:04 a.m. Oct. 1, 2013 - ACCESSWIRE
Zalicus' Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia 9:44 a.m. Sept. 27, 2013 - BusinessWire
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain 7:30 a.m. Sept. 9, 2013 - BusinessWire
Valuation
P/E Current
-0.54
P/E Ratio (with extraordinary items)
-0.76
Price to Sales Ratio
6.05
Price to Book Ratio
2.65
Enterprise Value to EBITDA
-0.12
Enterprise Value to Sales
0.31
Total Debt to Enterprise Value
0.27
Efficiency
Revenue/Employee
0.35
Income Per Employee
-1.23
Receivables Turnover
5.09
Total Asset Turnover
0.18
Liquidity
Current Ratio
1.95
Quick Ratio
1.95
Cash Ratio
1.76
Profitability
Operating Margin
-332.61
Pretax Margin
-356.72
Net Margin
-353.20
Return on Assets
-62.76
Return on Equity
-118.30
Return on Total Capital
-80.10
Return on Invested Capital
-88.67
Capital Structure
Total Debt to Total Equity
48.88
Total Debt to Total Capital
32.83
Total Debt to Total Assets
24.71
Long-Term Debt to Equity
28.30
Long-Term Debt to Total Capital
19.01
Zalicus Inc. ZLCS Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 12.3M 17.27M 46.74M 8.18M 12.55M
Cost of Goods Sold (COGS) incl. D&A 3.21M 5.6M 21.16M 40.44M -
COGS excluding D&A 0 0 0 33.23M -
Depreciation & Amortization Expense 3.21M 5.6M 21.16M 7.21M 5.37M
Depreciation 3.21M 5.08M 2.43M 2.06M 1.48M
Amortization of Intangibles - 520,000 18.74M 5.14M 3.89M
Gross Income 9.09M 11.67M 25.58M (32.25M) -
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 66.55M 33.24M 32.7M 10.4M 48.92M
Research & Development 55.3M 21.24M 23.01M - 41.42M
Other SG&A 11.26M 12M 9.69M 10.4M 7.5M
Other Operating Expense 0 0 0 0 0
Unusual Expense 4.83M (22.84M) 29.29M 0 1.09M
EBIT after Unusual Expense (4.83M) 22.84M (29.29M) 0 (1.09M)
Non Operating Income/Expense (4,000) (281,000) 32,000 20,000 91,000
Non-Operating Interest Income 2.26M 257,000 132,000 136,000 150,000
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 651,000 28,000 12,000 976,000 2.17M
Gross Interest Expense 651,000 28,000 12,000 976,000 2.17M
Interest Capitalized 0 0 - - 0
Pretax Income (60.68M) 1.22M (36.26M) (43.47M) (44.77M)
Income Tax (108,000) (67,000) (1.21M) (1.43M) (441,000)
Income Tax - Current Domestic (108,000) (67,000) (300,000) (34,000) 0
Income Tax - Current Foreign 0 0 (910,000) (1.39M) (441,000)
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income (60.58M) 1.28M (35.05M) (42.04M) (44.33M)
Minority Interest Expense 0 0 0 0 0
Net Income (60.58M) 1.28M (35.05M) (42.04M) (44.33M)
Extraordinaries & Discontinued Operations (4.56M) 14.1M 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 15.64M 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations (4.56M) (1.54M) 0 0 0
Net Income After Extraordinaries (65.13M) 15.39M (35.05M) (42.04M) (44.33M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (60.58M) 1.28M (35.05M) (42.04M) (44.33M)
EPS (Basic) (11.27) (0.06) (2.53) (2.59) (2.29)
Basic Shares Outstanding 5.78M 6.2M 13.72M 16.16M 19.47M
EPS (Diluted) (11.27) (0.06) (2.53) (2.59) (2.29)
Diluted Shares Outstanding 5.78M 6.22M 13.72M 16.16M 19.47M
EBITDA (54.25M) (15.97M) 14.04M (35.45M) (36.37M)
Zalicus Inc. ZLCS Filings
SEC Filings for Zalicus Inc.
Filing Date Document Date Type Category Amended
11/12/2013 11/11/2013 8-K Special Events
11/04/2013 09/30/2013 10-Q Quarterly Reports
11/04/2013 11/04/2013 8-K Special Events
11/01/2013 11/01/2013 8-K Special Events
10/15/2013 10/15/2013 8-K Special Events
10/02/2013 10/02/2013 8-K Special Events
09/27/2013 09/27/2013 8-K Special Events
09/09/2013 09/09/2013 8-K Special Events
09/03/2013 09/03/2013 8-K Special Events
08/05/2013 06/30/2013 10-Q Quarterly Reports
08/01/2013 08/01/2013 8-K Special Events
06/19/2013 06/19/2013 8-K Special Events
06/06/2013 06/06/2013 8-K Special Events
06/04/2013 06/04/2013 8-K Special Events
05/10/2013 05/10/2013 8-K Special Events
05/08/2013 05/08/2013 8-K Special Events
05/03/2013 03/31/2013 10-Q Quarterly Reports
05/02/2013 05/02/2013 8-K Special Events
05/01/2013 04/30/2013 8-K Special Events
04/29/2013 06/06/2013 DEF 14A Proxy Statement
SEC Filings provided by EDGAR Online, Inc.
ZLCS Zalicus Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=ZLCS&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ZLCS/quote
Stock Chart http://www.otcmarkets.com/stock/ZLCS/chart
Company Info http://www.otcmarkets.com/stock/ZLCS/company-info
Recent News http://www.otcmarkets.com/stock/ZLCS/news
Financials http://www.otcmarkets.com/stock/ZLCS/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ZLCS/filings
Short Sales http://www.otcmarkets.com/stock/ZLCS/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ZLCS/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ZLCS/research
Summary http://finance.yahoo.com/q?s=ZLCS
Historical Prices http://finance.yahoo.com/q/hp?s=ZLCS+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ZLCS
Basic Chart http://finance.yahoo.com/q/bc?s=ZLCS+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ZLCS+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ZLCS+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ZLCS+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ZLCS+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ZLCS+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ZLCS+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ZLCS+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ZLCS+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ZLCS+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ZLCS
Balance Sheet http://finance.yahoo.com/q/bs?s=ZLCS
Cash Flow http://finance.yahoo.com/q/cf?s=ZLCS+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ZLCS
Market Watch http://www.marketwatch.com/investing/stock/ZLCS
Bloomberg http://www.bloomberg.com/quote/ZLCS:US
Morningstar http://quotes.morningstar.com/stock/s?t=ZLCS
Bussinessweek http://investing.businessweek.com/research/st...icker=ZLCS
Barchart http://www.barchart.com/quotes/stocks/ZLCS
OTC Short Report http://otcshortreport.com/index.php?index=ZLCS
Investopedia http://www.investopedia.com/markets/stocks/ZLCS/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. It has a portfolio of clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA.
ZLCS Last Price: 1.22
Last Updated: November 28, 2013 8:15 PM EST
ZLCS Stock Message Board and Forum http://investorshangout.com/search?q=ZLCS&...mp;yt0=Go!
Zalicus Inc. ZLCS Officers and Executives
Name Age Officer Since Title
Mr. Frank W. Haydu 65 2004 Chairman
Dr. Mark H. N. Corrigan 55 2009 President, Chief Executive Officer & Director
Mr. Justin A. Renz 41 2006 Chief Financial Officer, Treasurer & Executive VP
Mr. William James O'Shea 63 2007 Independent Director
Dr. William L. Hunter 50 2009 Independent Director
Zalicus, Inc.
245 1st Street
3rd floor
Cambridge, Massachusetts 02142
Phone
1 6173017000
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$12.55M
Net Income
$-44.33M
2012 Sales Growth
53.3%
Employees
36.00
Annual Report Below for ZLCS
Zalicus Inc. ZLCS Recent Headlines
MarketWatch News on ZLCS
Zalicus to discontinue rheumatoid arthritis drug 10:38 a.m. Sept. 10, 2012 - MarketWatch.com
Pfizer, Affymetrix weigh on drug stocks 2:04 p.m. July 7, 2011 - Val Brickates Kennedy
Tuesday’s biggest advancing and declining stocks 2:35 p.m. July 5, 2011 - Kate Gibson
Drug stocks sluggish; Zalicus jumps 12:17 p.m. July 5, 2011 - Val Brickates Kennedy
Zalicus jumps 10% on stock rating 9:18 a.m. July 5, 2011 - Val Brickates Kennedy
5 reasons I can’t sell B. of A. — should you buy? 8:42 a.m. April 21, 2011 - Jeff Reeves
10 expert stock picks for 2011 12:02 a.m. Jan. 5, 2011 - Jeff Reeves
Zalicus trades sharply higher on heavy volume 1:28 p.m. Nov. 26, 2013 - Seeking Alpha
Zalicus: Where From Here? 12:02 p.m. Nov. 15, 2013 - Seeking Alpha
UPDATE: Oppenheimer Downgraded Zalicus 2:48 p.m. Nov. 11, 2013 - benzinga.com
Intel Buys ‘Kno’ to Reinforce Education Laptops Sideline and 2 Other Hot Stocks to Watch 11:35 a.m. Nov. 11, 2013 - Wall St. Cheat Sheet
Zalicus Plunges on Pain Drug Blowup 11:30 a.m. Nov. 11, 2013 - TheStreet.com
Zalicus' Z160 Fails, What Now? 11:05 a.m. Nov. 11, 2013 - Seeking Alpha
Zalicus: Investors Get Sucker Punched 10:58 a.m. Nov. 11, 2013 - Seeking Alpha
UPDATE: Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 7:32 a.m. Nov. 11, 2013 - benzinga.com
Key Issues Surrounding The Zalicus Catalyst Trade 8:56 a.m. Nov. 8, 2013 - Seeking Alpha
Clues And Controversy: Why Zalicus Shares Could Be Set For A Rally 9:08 a.m. Nov. 6, 2013 - Seeking Alpha
Where Is Zalicus After Trial Results? 2:06 p.m. Nov. 5, 2013 - Seeking Alpha
Recent FDA News Makes A Zalicus Trade Look Even More Compelling 5:27 a.m. Oct. 29, 2013 - Seeking Alpha
Zalicus: An Upcoming Catalyst With Huge Potential 11:06 a.m. Oct. 24, 2013 - Seeking Alpha
4 Biotechnology Stocks With Room To Climb 9:10 a.m. Oct. 15, 2013 - Seeking Alpha
A High Risk-High Reward Biopharma With Two Pending Catalysts 8:16 a.m. Oct. 4, 2013 - Seeking Alpha
Biotech Stock Mailbag: Bubble Debate, Cel-Sci, Zogenix, Zalicus 6:00 a.m. Oct. 4, 2013 - TheStreet.com
Zalicus Shares Nosedive Following News of 1-for-6 Reverse Split 3:57 p.m. Oct. 2, 2013 - benzinga.com
Greater Fools Love Delcath, Zalicus On Orphan Drug Derpitude 12:03 p.m. Oct. 2, 2013 - TheStreet.com
Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals 10:25 a.m. Sept. 20, 2013 - Seeking Alpha
AcelRx Pharmaceuticals To Submit NDA By End Of September, May Be Acquired Soon 7:55 a.m. Sept. 20, 2013 - Seeking Alpha
Press Releases on ZLCS
ELTK, AAPL, ZLCS and AGNC added to NASDAQ Active Stock Watch List at EPR 10:05 a.m. Nov. 27, 2013 - ACCESSWIRE
Bullish Stocks Analysis: Zalicus Inc, Camtek Ltd, JPMorgan Chase & Co, Nevada Gold Corp 9:01 a.m. Nov. 27, 2013 - ACCESSWIRE
Bearish Stocks Trend Analysis: Green Mountain Coffee Roasters, Zalicus Inc, Time Warner Cable, Baidu, Qihoo 360 Technology 8:47 a.m. Nov. 27, 2013 - PR Newswire
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent 8:00 a.m. Nov. 14, 2013 - PR Newswire
TrendingWallStreet.com Initiates Trend Research on TRMR, ENIP, STPFQ, and ZLCS 12:23 a.m. Nov. 13, 2013 - ACCESSWIRE
FDA Updates, Corporate Developments: Viropharma, 3D Systems Corporation, Cirrus Logic, Zalicus, The Boeing Company 8:53 a.m. Nov. 12, 2013 - PR Newswire
TrendingWallStreet.com Initiates Volume Research on TRMR, ENIP, STPFQ, and ZLCS 1:05 a.m. Nov. 12, 2013 - ACCESSWIRE
ZLCS, CLRX, DSCO and GALE added to NASDAQ Active Stock Watch List at GSR 10:19 a.m. Nov. 11, 2013 - ACCESSWIRE
Zalicus Reports Results from Phase 2 Clinical Trials of Z160 in Chronic Neuropathic Pain 8:30 a.m. Nov. 11, 2013 - BusinessWire
Closing of Over-Allotment Options, Receiving Orphan Drug Designations, Release of Clinical Data, and Obtaining Important Patents - Research Report on Galena, Zalicus, Infinity, Stemline and Insmed 8:00 a.m. Nov. 5, 2013 - PR Newswire
Zalicus Reports Financial Results for the Third Quarter 2013 7:30 a.m. Nov. 4, 2013 - BusinessWire
Zalicus Announces Positive Results of Z944 Phase 1b Clinical Study in Pain 8:30 a.m. Nov. 1, 2013 - BusinessWire
Under The Radar Big Pharma Partnership Opportunity for Zalicus,Targacept and ACADIA 5:16 a.m. Oct. 31, 2013 - ACCESSWIRE
Healthcare Companies Report Quarterly Financial Results - Research Report on Celgene, Natus, Merit Medical, Invacare, and Zalicus 9:00 a.m. Oct. 30, 2013 - PR Newswire
Zalicus Regains Compliance with Nasdaq Listing Requirements 7:30 a.m. Oct. 15, 2013 - BusinessWire
Zalicus Announces 1-for-6 Reverse Stock Split 4:01 p.m. Oct. 2, 2013 - BusinessWire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 8:00 a.m. Oct. 2, 2013 - PR Newswire
TSLA, AGNC, GERN and ZLCS added to Nasdaq Active Stock Watch List at GSR 9:04 a.m. Oct. 1, 2013 - ACCESSWIRE
Zalicus' Z160 Receives Orphan Drug Designation for the Management of Postherpetic Neuralgia 9:44 a.m. Sept. 27, 2013 - BusinessWire
Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain 7:30 a.m. Sept. 9, 2013 - BusinessWire
Valuation
P/E Current
-0.54
P/E Ratio (with extraordinary items)
-0.76
Price to Sales Ratio
6.05
Price to Book Ratio
2.65
Enterprise Value to EBITDA
-0.12
Enterprise Value to Sales
0.31
Total Debt to Enterprise Value
0.27
Efficiency
Revenue/Employee
0.35
Income Per Employee
-1.23
Receivables Turnover
5.09
Total Asset Turnover
0.18
Liquidity
Current Ratio
1.95
Quick Ratio
1.95
Cash Ratio
1.76
Profitability
Operating Margin
-332.61
Pretax Margin
-356.72
Net Margin
-353.20
Return on Assets
-62.76
Return on Equity
-118.30
Return on Total Capital
-80.10
Return on Invested Capital
-88.67
Capital Structure
Total Debt to Total Equity
48.88
Total Debt to Total Capital
32.83
Total Debt to Total Assets
24.71
Long-Term Debt to Equity
28.30
Long-Term Debt to Total Capital
19.01
Zalicus Inc. ZLCS Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 12.3M 17.27M 46.74M 8.18M 12.55M
Cost of Goods Sold (COGS) incl. D&A 3.21M 5.6M 21.16M 40.44M -
COGS excluding D&A 0 0 0 33.23M -
Depreciation & Amortization Expense 3.21M 5.6M 21.16M 7.21M 5.37M
Depreciation 3.21M 5.08M 2.43M 2.06M 1.48M
Amortization of Intangibles - 520,000 18.74M 5.14M 3.89M
Gross Income 9.09M 11.67M 25.58M (32.25M) -
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 66.55M 33.24M 32.7M 10.4M 48.92M
Research & Development 55.3M 21.24M 23.01M - 41.42M
Other SG&A 11.26M 12M 9.69M 10.4M 7.5M
Other Operating Expense 0 0 0 0 0
Unusual Expense 4.83M (22.84M) 29.29M 0 1.09M
EBIT after Unusual Expense (4.83M) 22.84M (29.29M) 0 (1.09M)
Non Operating Income/Expense (4,000) (281,000) 32,000 20,000 91,000
Non-Operating Interest Income 2.26M 257,000 132,000 136,000 150,000
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 651,000 28,000 12,000 976,000 2.17M
Gross Interest Expense 651,000 28,000 12,000 976,000 2.17M
Interest Capitalized 0 0 - - 0
Pretax Income (60.68M) 1.22M (36.26M) (43.47M) (44.77M)
Income Tax (108,000) (67,000) (1.21M) (1.43M) (441,000)
Income Tax - Current Domestic (108,000) (67,000) (300,000) (34,000) 0
Income Tax - Current Foreign 0 0 (910,000) (1.39M) (441,000)
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income (60.58M) 1.28M (35.05M) (42.04M) (44.33M)
Minority Interest Expense 0 0 0 0 0
Net Income (60.58M) 1.28M (35.05M) (42.04M) (44.33M)
Extraordinaries & Discontinued Operations (4.56M) 14.1M 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 15.64M 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations (4.56M) (1.54M) 0 0 0
Net Income After Extraordinaries (65.13M) 15.39M (35.05M) (42.04M) (44.33M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (60.58M) 1.28M (35.05M) (42.04M) (44.33M)
EPS (Basic) (11.27) (0.06) (2.53) (2.59) (2.29)
Basic Shares Outstanding 5.78M 6.2M 13.72M 16.16M 19.47M
EPS (Diluted) (11.27) (0.06) (2.53) (2.59) (2.29)
Diluted Shares Outstanding 5.78M 6.22M 13.72M 16.16M 19.47M
EBITDA (54.25M) (15.97M) 14.04M (35.45M) (36.37M)
Zalicus Inc. ZLCS Filings
SEC Filings for Zalicus Inc.
Filing Date Document Date Type Category Amended
11/12/2013 11/11/2013 8-K Special Events
11/04/2013 09/30/2013 10-Q Quarterly Reports
11/04/2013 11/04/2013 8-K Special Events
11/01/2013 11/01/2013 8-K Special Events
10/15/2013 10/15/2013 8-K Special Events
10/02/2013 10/02/2013 8-K Special Events
09/27/2013 09/27/2013 8-K Special Events
09/09/2013 09/09/2013 8-K Special Events
09/03/2013 09/03/2013 8-K Special Events
08/05/2013 06/30/2013 10-Q Quarterly Reports
08/01/2013 08/01/2013 8-K Special Events
06/19/2013 06/19/2013 8-K Special Events
06/06/2013 06/06/2013 8-K Special Events
06/04/2013 06/04/2013 8-K Special Events
05/10/2013 05/10/2013 8-K Special Events
05/08/2013 05/08/2013 8-K Special Events
05/03/2013 03/31/2013 10-Q Quarterly Reports
05/02/2013 05/02/2013 8-K Special Events
05/01/2013 04/30/2013 8-K Special Events
04/29/2013 06/06/2013 DEF 14A Proxy Statement
SEC Filings provided by EDGAR Online, Inc.
ZLCS Zalicus Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=ZLCS&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ZLCS/quote
Stock Chart http://www.otcmarkets.com/stock/ZLCS/chart
Company Info http://www.otcmarkets.com/stock/ZLCS/company-info
Recent News http://www.otcmarkets.com/stock/ZLCS/news
Financials http://www.otcmarkets.com/stock/ZLCS/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ZLCS/filings
Short Sales http://www.otcmarkets.com/stock/ZLCS/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ZLCS/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ZLCS/research
Summary http://finance.yahoo.com/q?s=ZLCS
Historical Prices http://finance.yahoo.com/q/hp?s=ZLCS+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ZLCS
Basic Chart http://finance.yahoo.com/q/bc?s=ZLCS+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ZLCS+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ZLCS+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ZLCS+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ZLCS+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ZLCS+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ZLCS+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ZLCS+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ZLCS+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ZLCS+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ZLCS
Balance Sheet http://finance.yahoo.com/q/bs?s=ZLCS
Cash Flow http://finance.yahoo.com/q/cf?s=ZLCS+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ZLCS
Market Watch http://www.marketwatch.com/investing/stock/ZLCS
Bloomberg http://www.bloomberg.com/quote/ZLCS:US
Morningstar http://quotes.morningstar.com/stock/s?t=ZLCS
Bussinessweek http://investing.businessweek.com/research/st...icker=ZLCS
Barchart http://www.barchart.com/quotes/stocks/ZLCS
OTC Short Report http://otcshortreport.com/index.php?index=ZLCS
Investopedia http://www.investopedia.com/markets/stocks/ZLCS/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
